Indivior Plc - ADR
INVVY
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.6B
Close$
Share Statistics
| Market cap | $4.60 Billion |
|---|---|
| Enterprise Value | $4.49 Billion |
| Dividend Yield | $0.64 (-) |
| Earnings per Share | $-0.36 |
| Beta | -0.06 |
| Outstanding Shares | 140,988,000 |
Return
| Return on Equity | -175.00% |
|---|---|
| Return on Assets | 21.05% |
| Return on Invested Capital | 81.10% |
Valuation & Multiples
| P/E Ratio | 12.98 |
|---|---|
| PEG | 14.53 |
| Price to Sales | 2.43 |
| Price to Book Ratio | -10.92 |
| Enterprise Value to Revenue | 3.48 |
| Enterprise Value to EBIT | 13.24 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...